Our History
Inception and Start-Up (2008–2010)
While working at Ensemble Therapeutics, a Flagship Ventures-funded company, from 2004 to 2008, Dr. Yumei Huang recognized a major market need for high-quality bioconjugation services. Many outsourced bioconjugates were either nonfunctional or performed poorly in biological assays. Although her primary role at Ensemble focused on core technology development, she was frequently asked to help biologists prepare bioconjugates for their studies. At the same time, she wanted to continue research she had begun at MIT on novel photocrosslinking reagents for studying membrane proteins.
In October 2008, Dr. Huang founded CellMosaic®, whose name was inspired by the fluid mosaic model of the cell membrane. Her initial plan was to support the company through bioconjugation services while continuing to develop new technologies. In December 2008, she established a laboratory at Gateway Park in Worcester, Massachusetts, as part of the Massachusetts Biomedical Initiatives (MBI) , the longest-running life sciences incubator in Massachusetts.
By February 2009, Dr. Huang had become fully self-employed, launched the CellMosaic website, and begun business operations. The company’s first project came from Professor Darryl J. Pappin’s laboratory at Cold Spring Harbor Laboratory. For this project, she prepared a unique mass-tagging reagent valued at $9,300. Professor Pappin, a friend and professional colleague, placed the order shortly after the laboratory was established because he had been unable to identify another company capable of preparing the compound.
Later that year, Dr. Frank Guarnieri, Chief Scientific Officer of the start-up PAKA Pulmonary Pharmaceuticals, visited Dr. Huang’s 200-square-foot laboratory after receiving a referral from a colleague. Despite CellMosaic’s limited resources at the time, he commissioned the development of a novel peptide–drug conjugate.
Dr. Guarnieri had previously used a similar conjugate produced by another company, but that conjugate could only be labeled at the peptide’s N-terminus. Dr. Huang redesigned the molecule with C-terminal labeling, improving its binding affinity by approximately tenfold. This success demonstrated CellMosaic’s ability to solve complex bioconjugation challenges and develop high-performance conjugates.
On November 30, 2010, CellMosaic was recognized by Mass High Tech as one of the “Five Startups to Watch” in New England. By March 2011, Dr. Huang had hired the company’s first employee and expanded operations into a 1,600-square-foot facility. As the company grew, she concluded that bioconjugation would become increasingly important to the life sciences industry and shifted her focus from membrane protein research to full-time work in bioconjugation.
Technology Development (2011–2016)
In January 2011, Syntarga contacted CellMosaic to evaluate the company’s ability to produce multiple duocarmycin antibody–drug conjugates with high drug-to-antibody ratios (DARs). Although the project did not proceed because Syntarga was acquired by Synthon later that year, the inquiry led Dr. Huang to an important realization: the hydrophilic linkers and crosslinking systems she was developing could potentially be adapted to achieve the high drug loading required for ADCs.
By July 2012, Dr. Huang had finalized the design of a new family of linkers based on sugar alcohol molecules and filed a Patent Cooperation Treaty (PCT) application covering AqueaTether® (AqT®) Technologies .
Her vision was to build an extensive library of versatile linkers that would capitalize on the unique properties of sugar alcohols, including their structural diversity, high hydrophilicity, and biocompatibility. Despite these advantages, sugar alcohols had not been widely explored for linker development, likely because of the technical difficulty involved in modifying and derivatizing them for practical applications. AqT® Technologies represented a significant advancement and established a foundation for new bioconjugation chemistries and drug delivery systems.
In September 2012, CellMosaic was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of General Medical Sciences of the National Institutes of Health (NIGMS/NIH). The grant supported the development of oxLink™ and sxLink™ technologies for the labeling, crosslinking, and detection of G protein-coupled receptors (GPCRs), building on Dr. Huang’s earlier research at MIT. The original proposal had been submitted in response to the 2009 NIH Challenge Grants in Health and Science Research program.
This success encouraged Dr. Huang to apply for the highly competitive U.S. Department of Defense Breast Cancer Research Program Breakthrough Award to support further development of the AqT® platform. Among 372 Level 1 applications submitted worldwide, CellMosaic was the only for-profit company among the 15 finalists recommended for funding in fiscal year 2014.
In December 2015, CellMosaic relocated from the MBI incubator laboratories to a larger facility at Cummings Properties in Woburn, Massachusetts. In April 2016, the company received the 2015 Joseph R. Carter Innovation Award from MBI and MassBio.
Product and Service Development (2017–Present)
In late 2016, CellMosaic introduced the PerKit® product line to enable customers to prepare high-quality bioconjugates in-house. The company was initially cautious about developing conjugation kits because similar efforts by other companies had not always been successful. However, CellMosaic was able to translate its proprietary manufacturing processes into user-friendly and effective kit formats.
The first product, the PerKit® HRP–Oligo Conjugation Kit, was launched on January 18, 2017. During that year, Cue Inc. purchased 78 reaction kits.
On May 12, 2017, CellMosaic launched its first standard reagent product, curcumin-β-D-glucuronide, in response to a customer request.
By December 29, 2017, the PerKit® product line had expanded to include antibody–drug conjugate kits. A total of 58 ADC reaction kits were sold in 2018.
On March 24, 2021, CellMosaic expanded its reagent and kit portfolio with the launch of the AqT® product line. The first product introduced was the AqT® Biotin Active Ester Antibody Labeling Kit.
On September 1, 2023, CellMosaic introduced Routine Synthesis™, a standardized conjugation service for medium- and large-scale ADC production. The service simplified custom bioconjugation procurement through a web-based ordering system and predefined synthesis options.